Thymic Stromal Lymphopoietin (TSLP): Evidence in Respiratory Epithelial-driven Diseases Including Chronic Rhinosinusitis with Nasal Polyps.

Autor: De Corso E; UOC Otorinolaringoiatria, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.Go F.Vito 1, Roma, Italy. eugenio.decorso@gmail.com., Hellings PW; The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members, Brussels, Belgium.; Laboratory of Allergy and Clinical Immunology Research Unit, Department of Microbiology, Immunology and Transplantation, KU Leuven, Louvain, Belgium.; Department of Otorhinolaryngology, Head and Neck Surgery, UZ Leuven, Louvain, Belgium., Fokkens WJ; Department of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Klimek L; Center for Rhinology and Allergology, Wiesbaden, 2HNO-University Clinic Charité, Berlin, Germany., Peters AT; Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Scadding GK; Department of Allergy and Rhinology, Royal National ENT Hospital, London, UK., Desrosiers M; Department of ORL-HNS, Universitat de Montreal, Montreal, Canada., Lee SE; Department of Surgery, Division of Otolaryngology-Head & Neck Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Mullol J; Rhinology Unit and Smell Clinic, Department of Otorhinolaryngology, Hospital Clinic, FRCB- IDIBAPS, Universitat de Barcelona, CIBERES. Barcelona, Catalonia, Spain.
Jazyk: angličtina
Zdroj: Current allergy and asthma reports [Curr Allergy Asthma Rep] 2024 Dec 05; Vol. 25 (1), pp. 7. Date of Electronic Publication: 2024 Dec 05.
DOI: 10.1007/s11882-024-01186-2
Abstrakt: Purpose of the Review: Thymic stromal lymphopoietin (TSLP) is increasingly recognized for its pivotal role in the pathogenesis of various epithelial-driven chronic inflammatory diseases. This review navigates the existing evidence on TSLP, with a particular focus on asthma, before delving into the current understanding of its role in chronic rhinosinusitis with nasal polyps (CRSwNP). We explore the role of TSLP in the pathogenesis of asthma and CRSwNP, two conditions often interconnected and collectively referred to as"Global Airway Disease". Additionally, this review assesses the therapeutic potential of TSLP inhibition as a treatment option for both CRSwNP and asthma. A systematic literature search was conducted; selected publications were used to describe the biology of TSLP, including its expression and diverse effects on inflammation.
Recent Findings: The role of TSLP in asthma is well established and supported by the efficacy of tezepelumab, the first anti-TSLP monoclonal antibody approved for both type 2 (T2)-high and T2-low severe asthma. TSLP may be a key contributor to CRSwNP pathogenesis as evidenced by genetic and mechanistic studies in which TSLP has been shown to regulate T2 inflammation and influence non-T2 responses. Preliminary data from the NAVIGATOR trial indicate that tezepelumab may reduce CRSwNP symptoms in patients with comorbid asthma. While further research is required to clarify the extent of TSLP contribution in CRSwNP, this review highlights the potential of anti-TSLP therapies as a novel approach for managing severe, uncontrolled CRSwNP. If these preliminary findings are confirmed, targeting TSLP could become a promising strategy to treat CRSwNP with or without comorbid asthma.
Competing Interests: Declarations. Human and Animal Rights Statement: This article does not contain any studies with human or animal subjects performed by any of the authors. Competing Interests: E. De Corso received lecture fees and participated to advisory boards for Sanofi, GSK, Regeneron, Astrazeneca. P. W. Hellings has received unrestricted research grants from Sanofi/Regeneron, Viatris and GSK, and honoraria for lectures and/or advisory boards by Sanofi/Regeneron, GSK, and AstraZeneca. W. J. Fokkens received consultation and/or speaker fees from Dianosic, GSK, Menarini, Novartis, Sanofi-Aventis/Regeneron and AstraZeneca. The department of Otorhinolaryngology of the Amsterdam University Medical Centre, location AMC, received grants for research in Rhinology from: Novartis, EU, GSK, and Sanofi-Aventis. L. Klimek reports grants from Allergopharma, MEDA/Mylan, ALK Abelló, LETI Pharma, Stallergenes, Sanofi, ASIT biotech, Lofarma Quintiles, AstraZeneca, GSK, and Inmunotk; and personal fees from Allergopharma, MEDA/Mylan, HAL Allergie, LETI Pharma, Sanofi, Allergy Therapeut, and Cassella Med, outside the submitted work. A. T. Peters has received research grants from Sanofi/Regeneron and AstraZeneca. She has served as a consultant for GSK, Chiesi, Merck, Sanofi Regeneron, Eli Lilly and AstraZeneca. G. K. Scadding received honoraria for articles, speaker and advisory boards: ALK, Bayer, Chiesi, GSK, Haleon, Noucor, Sanofi- Regeneron, and Viatris. Chair of BSACI rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in Allergy, Vice President and AR lead for EUFOREA, and Chair/ member Data Monitoring Committees on SLIT for ALK. M. Desrosiers received fee for consultation, speaker activity, advisory board by sanofi/ Regeneron, GSK. He also received research support from Sanofi/Regeneron, GSK. Equity holder, Probionase Therapies Inc. S. E. Lee has received clinical trial funding and served on advisory boards for AstraZeneca, Genentech, Lyra Therapeutics, GSK, Optinose, Sanofi Regeneron, Upstream Bio and holds equity in Diceros Therapeutics. J. Mullol reports personal fees and other from SANOFI-GENZYME & REGENERON, personal fees and other from NOVARTIS, grants, personal fees and other from VIATRIS / MEDA Pharma, grants and personal fees from NOUCOR / URIACH Group, personal fees from Menarini, personal fees from UCB, personal fees and other from AstraZeneca, grants, personal fees and other from GSK, personal fees from MSD, personal fees and other from Lilly, personal fees and other from GLENMARK, outside the submitted work. J. Mullol is a Section Editor of Current Allergy and Asthma Reports and was not involved in the peer-review or handling of the manuscript.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: